The unique event, which is among the first global events created to build excitement for the upcoming Olympic Games, sees French and Singaporeans athletes and artists coming together to revitalise the iconic skate park in Singapore

SINGAPORE, May 24, 2024 /PRNewswire/ — In the lead up to the Paris 2024 Olympic Games, the Embassy of France in Singapore is organising a special two-day celebration of sports and arts aptly titled Artletics – making it among the first celebratory events organised around the world to drum up excitement for the global sports meet.

In collaboration with local partner Art Outreach and supported by the Singapore Tourism Board, the event happening on 25 and 26 May sees urban sports athletes and urban artists from both countries converging at the 18-year-old Somerset Skate Park to immerse Singaporeans in a joint showcase of their talents.

The event’s focus on urban sports gives a nod to the inclusion of the category into the upcoming Paris 2024 Olympic Games, which includes sports like BMX, skateboarding and breaking. It also runs parallel to the plans to transform the Place de la Concorde in Paris into an urban sports space. The unique collaboration also serves as a bridge between France and Singapore, deepening cultural ties through a shared passion for artistic expression and athleticism.

Ambassador of France to Singapore Her Excellency Minh-di Tang said, ‘Artletics embodies the spirit of street culture and celebrates artists and athletes striving for excellence, creativity and team spirit in the city where they leave lasting legacies and drive positive change in society. These core values pay homage to what the Olympic Games stand for, which France is hosting for the third time this year. Through Artletics, we want to showcase the best of French and Singaporean artistry, athleticism and sportsmanship, strengthening the cross-cultural partnerships our countries have enjoyed for many years.”

Somerset Skate Park transformed into a vibrant urban playground

Artletics caps off a month-long line up of programmes under the vOilah! France Singapore Festival – an annual cultural festival organised by the Embassy of France in Singapore to demonstrate French creativity and innovation through the power of cross-cultural collaborations.

In the spirit of enabling cultural exchanges, the Somerset Skate Park in the heart of Orchard Road is transformed into a dynamic space as orchestrated by urban artists from Singapore and France.

Three visual artists from Singapore – Zero, Spaz, and Simpleproblembeings – worked alongside French muralist Elsa Martino and graffiti artist Kekli to enliven the space by decorating the walls and the ramps of the skate park with vibrant designs. Supported by Singapore’s urban art collective RSCLS, these artists also will lead the public in engaging art jam sessions to partake in a collaboration of community artwork.

First to utilise the redecorated space are French skateboarding athlete Max Berguin, Champion of the France Street Skateboard 2023 and Singaporean urban sport communities in the field of skateboarding, breaking, BMX, bike trials, parkour and yo-yo who will be displaying their talents to spectators.

The event also features adrenaline-inducing urban sports showcases, opportunities for the public to take part in workshops conducted by local urban sports groups, as well as music sets in the evening by Singaporean DJs Kiat and Intriguant.

“Artletics is a vibrant celebration of the creative spirit that bridges French and Singaporean cultures through youth, urban sports and art,” said Mae Anderson, Chairman of Art Outreach. “We are thrilled to see French and Singaporean artists and skateboarders come together, transforming Somerset Skate Park into a collaborative canvas. We hope this event serves as a great opportunity for everyone to experience the power of art, athletics, while fostering a sense of belonging, inclusion and community spirit.”

More details of the festival and the programme can be found at www.voilah.sg/artletics.

-END-

About vOilah! 2024

vOilah! 2024 returns from 25 April to 26 May 2024. Presented by the Embassy of France in Singapore, this year’s edition will focus on celebrating the dreams and passions of artists and athletes, bringing experiences that make life more vibrant through strong connections between the French and Singaporean communities.

This year, visitors can look forward to 19 programmes covering audiovisual arts, performing arts, visual arts, lifestyle, sports, education, science, music. With the support of more than 50 partners, vOilah! 2024 is a culmination of vibrant and dynamic experiences that will strengthen an appreciation of arts, culture and innovative collaborations between our countries.

For more information, visit www.voilah.sg/artletics/

About Art Outreach

Art Outreach, established in 2003, passionately promotes art appreciation and strengthens the local art ecosystem. We also empower practitioners through professional development support and an incubatory art space. Our year-round programmes, tailored to diverse audiences, include educational talks, art tours, exhibitions, and workshops, fostering a deeper understanding and appreciation of art and artists within the community. By supporting a wide range of artists and art shows, we actively promote plurality and advocacy within the arts, championing inclusivity and celebrating a rich tapestry of artistic expression. Art Outreach has been an IPC charity since inception, and has been a multiple-year recipient of the Commissioner of Charities governance award. We are led by a deeply committed board and nurture a dynamic and cohesive team culture.

For more information, please visit www.artoutreachsingapore.org/

Source

SUZHOU, China and ROCKVILLE, Md., May 24, 2024 /PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that its four abstracts selected for presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting are now available on ASCO’s official website. These abstracts report on the company’s three lead drug candidates, including olverembatinib (HQP1351), the first and only China-approved third-generation BCR-ABL inhibitor; lisaftoclax (APG-2575), a BCL-2 selective inhibitor; and APG-2449, a FAK/ALK/ROS1 inhibitor.

Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting taking place on May 31 – June 4, 2024 in Chicago, IL. The ASCO Annual Meeting showcases the most cutting-edge research in clinical oncology and state-of-the-art advanced cancer therapies and is the world’s most influential and prominent scientific gathering of the clinical oncology community.

“It is our pleasure to present the latest data on our key drug candidates at the ASCO Annual Meeting for the seventh consecutive year,” said Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma. “These encouraging results once again highlight Ascentage Pharma’s robust capabilities in global innovation and clinical development. Going forward, we will further expedite our clinical development programs globally in the hope of benefitting more patients in China and around the world as soon as possible.”

These four clinical studies to be presented at this year’s ASCO Annual Meeting are as follows:

The details of these abstracts are as follows:

Oral Report

Olverembatinib (HQP1351)

Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST) and paraganglioma

Abstract#: 11502

Session Title: Sarcoma

Date and Time: June 3, 2024, Monday, 3:00 PM – 6:00 PM (Central Time)

First Author: Haibo Qiu, MD, PhD, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.

Highlights:

Background: SDH-deficient GIST is a rare type of GIST, mainly observed in the stomach of children, adolescents, and young adults under 30 years of age. No active targeted therapies have been identified in this subset of GIST. Olverembatinib, approved in China for the treatment of patients with chronic myeloid leukemia, has shown promising clinical efficacy in SDH-deficient GIST. In this abstract, the study reports updated efficacy data of olverembatinib in SDH-deficient GIST and preliminary efficacy data in paraganglioma, an SDH-deficient-related tumor.

Introduction: The aim of this study was to evaluate the safety and efficacy (per RECIST v1.1) of olverembatinib in patients with SDH-deficient GIST and other solid tumors. Olverembatinib was administered orally once every other day (QOD) in 28-day cycles.

Patient enrollment and methods: As of December 27, 2023, 26 patients with SDH-deficient GIST (confirmed by immunohistochemistry [IHC] assay) had received ≥1 dose of olverembatinib (median [range] age, 30 [13-56] years), and 25 of them had received 1-4 tyrosine kinase inhibitors (TKIs; 42.3% of patients received ≥3 TKIs). Olverembatinib was administered OQD in doses ranging from 30 to 50 mg (30 mg [n = 6]; 40 mg [n = 14]; 50 mg [n = 6]). This study also enrolled 6 patients with paraganglioma.

Efficacy results:

• In the 26 patients with SDH-deficient GIST, the median (range) duration of treatment was 15.6 (1.8-42.3) months. 6 of those patients achieved partial responses (PR); another 18 patients achieved stable diseases (SD) lasting > 4 cycles. The clinical benefit rate (CBR, complete response [CR] + PR + SD > 4 cycles) was 92.3% (24/26) and the longest treatment duration was 40 months. After a median (range) follow-up of 17.0 (4.1-57.5) months, the median (range) progression-free survival (PFS) was 25.7 months (12.1-not reached [NR]).
• Among the 6 patients with paraganglioma, 5 achieved SDs > 4 cycles, with a CBR of 83.3% and a median (range) PFS of 8.25 (1.87-NR) months.

Safety results: The adverse event profile was the same as previously reported (Qiu H, et al, J Clin Oncol 41:11540), with no newly emergent safety issues observed.

Conclusions: Olverembatinib was well tolerated. In patients with SDH-deficient GIST, olverembatinib demonstrated a CBR exceeding 90% and significantly prolonged the estimated median PFS, indicating the potential benefit of this treatment and providing a benchmark for future studies in this rare subtype of GIST.

Poster Presentations

Lisaftoclax (APG-2575)

Safety and efficacy of lisaftoclax, a novel BCL-2 inhibitor, in combination with azacitidine in patients with treatment-naïve or relapsed or refractory acute myeloid leukemia

Abstract#: 6541

Session Title: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Date and Time: June 3, 2024, Monday, 9:00 AM – 12:00 PM (Central Time)

First Author: Huafeng Wang, MD, PhD, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

Highlights:

Background and introduction: Early studies showed that lisaftoclax in combination with various agents can synergistically induce apoptosis in acute myeloid leukemia (AML). This poster presents follow-up safety and efficacy data from a Phase Ib/II study of lisaftoclax combined with azacitidine (AZA) in adults with AML.

Patient enrollment and methods:

• This study enrolled elderly (≥75 years)/unfit treatment-naïve (TN) patients with AML who were intolerant of standard induction chemotherapies and patients (≥18 years) with relapsed/refractory (R/R) AML. Lisaftoclax (400/600/800 mg) was administered orally once daily in 28-day cycles. In the first treatment cycle, a daily ramp up schedule was used to prevent tumor lysis syndrome (TLS). AZA was administered once daily on D1-D7 at 75 mg/m².
• As of January 25, 2024, 76 patients with AML were enrolled, including 37 patients with R/R AML and 39 elderly/unfit patients with TN AML who were intolerant of standard induction chemotherapies. The median (range) age was 66 (20-81) years, and 61.8% of the patients were male.

Efficacy results:

• In patients with R/R AML treated with lisaftoclax combined with AZA, the overall response rate ([ORR]=CR + CRi + morphologic leukemia-free state [MLFS] + PR) was 72.7%, the composite complete remission rate (CRc = CR + CRi) was 45.5%. In the 600 mg cohort (n=30), the median duration of treatment was 3.8 months, the ORR was 76.7%, the CRc was 50.0%, the median time to CRc was 2.5 months, the median PFS was 10.2 months, and the median overall survival (OS) was 14.7 months.
• Among patients with TN AML treated with lisaftoclax combined with AZA, the ORR was 64.1%, the CRc was 51.3%. In the 600 mg cohort (n=29), the median duration of treatment was 3.3 months, the median time to CRc was 1.9 months. The median PFS was not reached.
• 600 mg lisaftoclax combined with AZA was established as the recommended Phase II dose (RP2D).

Safety results: All patients treated with lisaftoclax combined with AZA reported treatment-emergent adverse events (TEAEs), with 89.5% experiencing Grade 3/4 TEAEs and 43.4% experiencing serious adverse events (SAEs). Common TEAEs included neutropenia (60.5%), thrombocytopenia (60.5%), diarrhea (42.1%), hypokalemia (40.8%), pyrexia (35.5%), and vomiting (30.3%). Grade ≥ 3 TEAEs reported in ≥ 10% of patients included neutropenia (57.9%), thrombocytopenia (50.0%), anemia (27.6%), pneumonia (17.1%), and febrile neutropenia (10.5%). No TLS was reported. The 30-/60-day mortality rates were 1.3% and 3.9%, respectively.

Conclusions: These data support a promising role for the new Bcl-2 inhibitor lisaftoclax combined with AZA for the treatment of elderly/unfit TN patients with AML intolerant of standard induction chemotherapies and patients with R/R AML, especially given a potentially favorable safety profile in terms of TLS, the incidence of neutropenic fever, and low early mortality. A Phase III randomized, double-blind study is being conducted to determine whether lisaftoclax combined with AZA improves the survival of elderly/unfit TN patients with AML intolerant of standard induction chemotherapies.

Updated efficacy and safety results of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM)

Abstract#: 7078

Session Title: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Date and Time: June 3, 2024, Monday, 9:00 AM– 12:00 PM (Central Time)

First Author: Masa Lasica, MBBS, FRACP, FRCPA, St Vincent’s Hospital, Melbourne, Victoria, Australia.

Highlights:

Background: Lisaftoclax is a novel, oral, highly selective, potent Bcl-2 inhibitor. Lisaftoclax can overcome resistance to ibrutinib in ibrutinib-insensitive RPCI-WM1 models. In other non-Hodgkin lymphoma (NHL) models (including DOHH2 follicular lymphoma models and OCI-LY1 diffuse large B-cell lymphoma [DLBCL] models), lisaftoclax combined with ibrutinib has a strong synergistic antitumor effect.

Introduction: This is an open-label, multicenter, global Phase Ib/II study designed to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of lisaftoclax monotherapy or in combinations with agents such as ibrutinib/rituximab in patients with WM.

Patient enrollment and methods:

• In this study, patients with WM were enrolled in 3 arms, including Arm A: lisaftoclax monotherapy in patients resistant or intolerant to prior treatment with Bruton’s tyrosine kinase inhibitors (BTKis); Arm B: lisaftoclax combined with ibrutinib in treatment-naïve patients with WM; and Arm C: lisaftoclax combined with rituximab in BTKi-naïve patients with relapsed/refractory WM.
• Lisaftoclax was orally administered once daily in 28-day cycles. Lisaftoclax was gradually escalated from the starting dose of 400 mg to 1,200 mg. As of January 25, 2024, a total of 46 patients were enrolled in the study (Arm A [n=14] at doses of up to 1,000 mg; Arm B [n=24] at doses of up to 1,200 mg; Arm C [n=8] at doses of up to 800 mg).

Efficacy results:

• The median (range) durations of treatment were 11 (1-28), 23.5 (1-34), and 11.5 (5-33) months for Arms A, B, and C, respectively.
• The objective response rates (ORRs; PR, very good partial response [VGPR], CR) were 41.7%, 90.9%, and 37.5% for Arms A, B, and C, respectively.
• In Arm A, patients with wild-type CXCR4 (n =7) had better overall response to lisaftoclax than the CXCR4^mut group (n = 3).
• In Arms B and C, no significant differences between patients with/without CXCR4^mut were observed.

Safety results:

• In Arm B, 1 dose-limiting toxicity (DLT, grade 3 clinical TLS), attributed to pre-existing renal impairment, occurred at 1,200 mg; and 1 grade 3 laboratory TLS, primarily attributed to dehydration and concomitant symptomatic therapies, occurred at 1,000 mg. Abnormal electrolytes was resolved without recurrence after 1 day of drug interruption.
• Grade ≥ 3 lisaftoclax-related adverse events (AEs) included neutropenia (15.2%), thrombocytopenia (4.3%), decreased leukocytes (4.3%), TLS (4.3%), anemia (2.2%), weight loss (2.2%), and septic shock (2.2%).
• Ventricular arrhythmia was not observed.
• One patient required dose reduction because of neutropenia.
• The maximum-tolerated dose (MTD) was not reached.
• Lisaftoclax combined with ibrutinib showed a PK exposure comparable to lisaftoclax or ibrutinib alone, indicating no potential drug-drug interactions (DDIs).

Conclusions: Lisaftoclax alone and combined with ibrutinib or rituximab was well tolerated and demonstrated measurable effects in patients with treatment-naïve or BTKi-treatment-failed WM.

APG-2449

Updated study results of novel FAK/ALK/ROS1 inhibitor APG-2449 in patients (pts) with non-small-cell lung cancer (NSCLC) resistant to second-generation ALK inhibitors.

Abstract#: 3124

Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Date and Time: June 1, 2024, Saturday, 9:00 AM – 12:00 PM (Central Time)

First Author: Yuxiang Ma, MD, PhD, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.

Highlights:

Background: ALK inhibitors increase FAK pathway gene expression in ALK⁺ NSCLC cell lines, with the highest induced expression in drug-tolerant persister cells. This suggests that FAK pathway activation is involved in the mechanism that leads to ALK TKI resistance in ALK⁺ NSCLC. APG-2449 is an orally active FAK inhibitor and a third-generation ALK/ROS1 TKI that has shown potent antitumor activity in preclinical models and clinical studies. This poster reports further safety and efficacy data of APG-2449.

Patient enrollment and methods:

• This study comprises a dose-escalation portion and a dose-expansion portion. 1,200 mg daily (QD) was determined as the RP2D. There are two cohorts in the dose-expansion portion: Cohort 1 included patients with NSCLC who were resistant to second-generation ALK TKIs; Cohort 2 included patients with NSCLC who were ALK or ROS1 TKI naïve.
• As of December 9, 2023, a total of 144 patients with NSCLC, mesothelioma, or ovarian cancer were treated with APG-2449 at doses ranging from 150 – 1,500 mg. The median (range) age of patients was 53 (21-78) years and 53.5% were female.

Efficacy results:

• The ORRs of APG-2449 in patients with ROS1 and ALK TKI-naïve NSCLC (n=36) were 68.2% (15/22) and 78.6% (11/14), respectively. Of the 22 patients with NSCLC resistant to second-generation ALK inhibitors and without targetable bypass gene mutations (e.g., KRAS G12C, BRAF V600E), 9 achieved PRs (9/22; 40.9%). Among the patients treated with RP2D, 12 had brain metastasis at baseline, 9 of whom achieved intracranial PR, resulting in an intracranial ORR of 75.0%.
• Biomarker analysis found that in patients with NSCLC that was resistant to second-generation ALK TKIs, PFS was correlated with phosphorylated FAK (pFAK) levels in the tumor tissue, suggesting that patients with higher pFAK levels were more likely to benefit from APG-2449.

Safety results: A total of 129 (89.6%) patients had treatment‑related adverse events (TRAEs), the most frequent of which were elevated serum creatinine (49.3%), increase in alanine aminotransferase (42.4%), increase in aspartate aminotransferase (36.1%); nausea (28.5%); vomiting (23.6%); diarrhea (22.9%); and decreased leukocyte count (22.2%). In all, 20 (13.9%) TRAEs were grade ≥ 3.

Conclusions: APG-2449 demonstrated preliminary efficacy in patients with NSCLC whose disease was TKI naïve and resistant to second-generation ALK inhibitors, especially in brain metastases. Biomarker analysis showed that high pFAK expression levels in baseline tumor tissue correlated with improved APG-2449 treatment responses in patients with NSCLC resistant to second-generation ALK TKIs.

*Olverembatinib is an investigational drug that has not been approved for any indication outside the Chinese mainland.

*Lisaftoclax and APG-2449 are investigational drugs that have not been approved in any country and region.

About Ascentage Pharma

Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK.

Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company has built a pipeline of 9 clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs). Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The company is conducting more than 40 Phase I/II clinical trials, including 5 global registrational phase III studies, in the US, Australia, Europe, and China. Ascentage Pharma has been designated for multiple Major National R&D Projects, including five Major New Drug Projects, one New Drug Incubator status, four Innovative Drug Programs, and one Major Project for the Prevention and Treatment of Infectious Diseases.

Olverembatinib, the company’s core drug candidate developed for the treatment of drug-resistant chronic myeloid leukemia (CML) and the company’s first approved product in China, has been granted Priority Review Designations and Breakthrough Therapy Designations by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA). To date, the drug had been included into the China 2022 National Reimbursement Drug List (NRDL). Furthermore, olverembatinib has been granted an Orphan Drug Designation (ODD) and a Fast Track Designation (FTD) by the US FDA, and an Orphan Designation by the EMA of the EU. To date, Ascentage Pharma has obtained a total of 16 ODDs from the US FDA and 1 Orphan Designation from the EMA of the EU for 4 of the company’s investigational drug candidates.

Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships with numerous renowned biotechnology and pharmaceutical companies and research institutes such as UNITY Biotechnology, MD Anderson Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, MSD, and AstraZeneca. The company has built a talented team with global experience in the discovery and development of innovative drugs and is setting up its world-class commercial manufacturing and Sales & Marketing teams. One pivotal aim of Ascentage Pharma is to continuously strengthen its R&D capabilities and accelerate its clinical development programs, in order to fulfil its mission of addressing unmet clinical needs in China and around the world for the benefit of more patients.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, Ascentage Pharma undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.

Source

Portal Will Enable Participants and Attendees to Book Rooms for November Event in Baku

BAKU, Azerbaijan, May 24, 2024 /PRNewswire/ — Azerbaijan, the host of COP29, today unveiled its interactive accommodation portal, the system that will enable participants and attendees to book hotel rooms and other lodging for the United Nations Climate Change Conference being held in Baku in November.

COP29 Launch of accommodation platform

In a press conference at the COP29 Office, Azada Huseynova, Deputy Chair of the State Tourism Agency of the Republic of Azerbaijan, said the accommodation system has been designed to ensure that a range of room types and locations will be available to people who want to attend the event.

The accommodation platform will be available for reservations https://cop29-accommodation.bnetwork.com from 17:00 today, on 23^rd May, 2024.

“We will be ready to welcome the world to Baku. We have studied the experiences of previous COP host countries and how they approached their accommodation programs and have integrated some elements of those practices into our plans as COP host country,” Ms. Huseynova said. “We have put in place the infrastructure that will ensure that participants from around the world can make their accommodation booking in a smooth and speedy way.”

The State Tourism Agency is working with hotels, on-line accommodation marketplaces, and other residential and lodging locations in the city and region, to ensure that the event will be able to host the full complement of attendees comfortably and enjoyably.      

The lodging made available in the system today is the first phase of a comprehensive rollout. Further phases will release additional rooms at additional hotels and lodging facilities.

The hotels included in the platform have been selected on the basis of quality, location and transportation services that will be arranged for the event. The Agency audited more than 300 accommodation establishments, and approximately 200 have been classified and received a star rating. About 40 hotels that did not earn a star classification were given a period to improve facilities and performance before being re-audited.

Ms. Huseynova also provided details of a customer service training program being undertaken by the State Tourism Agency in advance of COP29. Approximately 2,000 employees from about 300 establishments in the cities of Baku and Sumgayit, and the wider Absheron region are participating.

In addition, the Agency plans to provide training and certification to 200 tourist guides, and training to a further 1,000 tourism volunteers, who will be assigned to hotels to support guests during COP29.

COP29 Launch of accommodation platform

COP29 Launch of accommodation platform

COP29 Launch of accommodation platform

Source

HO CHI MINH CITY, Vietnam, May 23, 2024 /PRNewswire/ — SALTO WECOSYSTEM, a leading provider of integrated access control solutions, is delighted to announce its participation in the highly anticipated HoSkar Night Phnom Penh event. This collaboration aims to showcase Salto’s innovative solutions tailored for the real estate and hospitality sectors and shares success stories contributed to hospitality property in Cambodia and the region.

HoSkar Night Phnom Penh is brought by WeHub, hosted by Savills Hotels and in partnership with Salto Wecosystem, a prominent coworking and innovation hub in the heart of Cambodia’s capital city. Scheduled to take place in the vibrant city of Phnom Penh on 29th May 2024, the event will bring together industry leaders, technology enthusiasts, and innovators to explore the latest trends and advancements in various sectors.

Salto’s participation at the event will feature the display of its latest access control and management systems with demo wire-free locks stand and artboards in a cozy gallery vibe to storytelling and showcasing most well-known project reference in Cambodia, which is a harmonious blend of technology, aesthetics, and sustainability. Their commitment to delivering security solutions aligns with luxury resorts’ vision of providing an unforgettable, eco-friendly experience for its guests. Attendees will have the opportunity to learn how Salto’s technologies can streamline operations, enhance security, and deliver personalized experiences for real estate and hospitality businesses.

“We are thrilled to be part of the HoSkar Night event in Phnom Penh and to partner with WeHub to enhance the guest access experience for every single property and project across Cambodia and the surrounding region,” said Don Dinh, General Director for Salto Wecosystem Vietnam, Cambodia & Laos.

Beyond showcasing its technologies, Salto Wecosystem is more than just a group of companies and individuals – it is a community born out of a common goal: to empower access, in every sense – access to places, experiences, and opportunities. The company believes that the industry still has a long way to go, and it wants to play an active role in the exciting journey ahead.

“The Cambodia hospitality and real estate market is evolving rapidly, driven by global trends, and increasing local living standards. Engaging with local and international experts is crucial for staying updated and sharing market knowledge. The HoSkar Night event is tailored to connect local and foreign experts in a vibrant, engaging event, creating a community of business-minded individuals.” said Mauro Gasparotti, Founder of WeHub. “We are delighted to have Salto Wecosystem as a partner for this event, bringing new technology and solutions to the hospitality & real estate sectors”.

For more information about Salto Wecosystem and its participation in HoSkar Night Phnom Penh, please visit SALTO WECOSYSTEM: Empowering smarter access. 

To learn more about the event and inquire to attend, please visit https://hoskarnight.com/register/. For further inquiries or information, please contact the event organizers at Thi@wehubyou.com.

About Salto Wecosystem:

Salto Wecosystem is a leading provider of smart access solutions, dedicated to empowering businesses and individuals with seamless, secure, and personalized access to more experiences and opportunities. With a mission to enrich lives by enabling smarter access, Salto is at the forefront of the evolving access control and management landscape, delivering innovative technologies that redefine the way we interact with the spaces and services around us.

Let’s stay connected @saltowecosystem

Instagram: https://www.instagram.com/saltowecosystem/

YouTube: https://www.youtube.com/@saltowecosystem

LinkedIn: https://www.linkedin.com/company/salto-wecosystem/

Hotline: (+84) 2873000027

About WeHub:

WeHub is one of the most vibrant hospitality and real estate communities in Vietnam and Southeast Asia. WeHub was founded with the vision to connect businesses, people and ideas. The platform offers the latest trends and insights while facilitating business connections within the real estate and hospitality industries through various activities, including Meet The Experts conferences (MTE), HoSkar Night networking events, SIF masterclasses, and WeTalk private meetings for lead generation.

Follow WeHub’s official channels at:

LinkedIn: https://shorturl.at/Rw9GA 

Facebook: https://shorturl.at/YKnlY 

Contact WeHub for event collaboration: Host@wehubyou.com.

Source

Advanced TAVI Procedure on Patient with Severe Aortic Stenosis

KUALA LUMPUR, Malaysia, May 23, 2024 /PRNewswire/ — Pantai Hospital Kuala Lumpur (PHKL), a leader in medical excellence and patient care, has achieved another significant medical milestone with the successful launch of its Transcatheter Aortic Valve Implantation (TAVI) program. TAVI is a minimally invasive procedure designed to replace a narrowed aortic valve that does not open properly. It is typically performed through a small incision in the groin, using a catheter to implant a new valve under x-ray guidance. The complex procedure is performed by a TAVI team led by PHKL’s Senior Consultant Cardiologist Dr. Yee Kok Meng on patients suffering from severe aortic stenosis, a condition in which the aortic valve narrows and impedes blood flow from the heart to the body.

“Traditionally, these very sick heart patients were treated surgically by replacing the damaged heart valve with an artificial valve via open heart surgery. However such operations especially in the elderly population or those with multiple comorbidities may be very high risk. Now with TAVI, we are able to offer such patients an alternative approach which is both minimally invasive and much safer” said Dr Yee.

“At Pantai Hospital Kuala Lumpur, I am especially glad we are able to ramp up the TAVI program this year thanks to the support of the PHKL hospital management and all the staff involved. Due to the complexity of the procedure, TAVI requires a teamwork approach, and to this end PHKL has really provided all the support required to build up a dedicated TAVI team, which I think is crucial to ensure that the excellent results in terms of patient care and clinical outcomes are maintained,” added Dr Yee. Over the past month, two patients diagnosed with critical aortic stenosis, including an 83-year-old gentleman from Ipoh, and a 69 year-old Indonesian recovering from a recent stroke underwent TAVI successfully. Both patients were discharged home within 48 hours of the procedure.

The Heart Centre at Pantai Hospital Kuala Lumpur has been at the forefront of treating complex heart conditions with cutting-edge technologies. This successful procedure not only represents a personal victory for the patient and Dr. Yee but also sets a benchmark for cardiac care standards nationwide.

To ensure the health of your heart continues to play the right rhythms, PHKL emphasises the importance of early detection and preventive measures. PHKL’s Heart Screening Package offers various assessments tailored to meet individual needs and lifestyles. From stress tests and echocardiograms to cardiac CT heart scans, our cardiologists are equipped to detect potential heart issues early and to ensure your heart is performing at its best.

“The success of such advanced procedures at PHKL is a testament to the expertise and dedication of our medical teams and their relentless pursuit of excellence in healthcare,” said Erica Lam, Chief Executive Officer of Pantai Hospital Kuala Lumpur. “We are proud to provide our patients with access to some of the most sophisticated treatment options available in the world right here in Malaysia.”

Pantai Hospital Kuala Lumpur remains dedicated to enhancing patient care through innovation and expertise, contributing significantly to the advancements in the medical field, particularly in the treatment of cardiovascular diseases.

For more information about PHKL Heart Screening Package, please visit Pantai Hospital Kuala Lumpur’s website: www.pantai.com.my/kuala-lumpur or visit Pantai Hospital Kuala Lumpur for a consultation and find out more about how you can stay ahead of heart disease.

Dr. Yee Kok Meng, Consultant Cardiologist
MBChB (Edin), MD (Cardiology, UK), M C P (UK), FACC (USA)

Dr Yee is a Senior Consultant Cardiologist at Pantai Hospital Kuala Lumpur since 2005, and has over 20 years of clinical experience as an Interventional Cardiologist. He obtained his degree in Internal Medicine at the University of Edinburgh, UK in 1993. He subsequently completed his training and specialised in Cardiology at Cambridge University in 2001. He was then offered a fellowship in Interventional Cardiology by the University of Toronto, Canada. Based at the Toronto General Hospital, Dr Yee gained vast experience in all aspects of interventional cardiology procedures. He subsequently returned to Malaysia in August 2002 Dr Yee has contributed significantly to the field of cardiology and has published widely in respected scientific journals. In 2002, the University of Edinburgh awarded Dr Yee the postgraduate MD doctorate in Cardiology with distinction. He has vast experience in a wide range of interventional procedures and performs most of his cases via the transradial route. He is also experienced with the use of various adjunctive devices and therapies such as rotational atherectomy, intravascular ultrasound (IVUS), OCT and coronary doppler wire (Pressure Wire).

About Pantai Hospital Kuala Lumpur
For 5 decades now, Pantai Hospital Kuala Lumpur (PHKL) has remained the heartbeat of Kuala Lumpur, steadfastly dedicated to delivering exceptional care and accessible cutting-edge technology to patients from all walks of life. Our journey began in 1974, with just 68 beds and a team of 20 medical specialists. Fast forward to the present day, we stand as a healthcare icon, operating 380 beds and home to over 200 consultants, each specialising in diverse medical and surgical disciplines.

At Pantai Hospital Kuala Lumpur, we are unwavering in our commitment to provide quality healthcare services while fostering clinical research and trials. We take pride in championing clinical excellence, service quality, and operational efficiency. Our pursuit of excellence has earned us accreditations from the Malaysian Society for Quality in Health (MSQH) and the Joint Commission International (JCI). Additionally, we are honoured to hold certification as a Baby Friendly Hospital and a preferred hospital in Malaysia by the World Health Organization (WHO).

As we celebrate our 50th anniversary, Pantai Hospital Kuala Lumpur reaffirms its role as a pillar of the city, offering world-class healthcare services, innovative treatments, and a legacy of excellence.

Source

TAIPEI, May 22, 2024 /PRNewswire/ — GIGABYTE, the world’s leading computer brand, is poised to captivate audiences at this year’s COMPUTEX with its latest offerings. From user-friendly designs to groundbreaking advancements in AI, visitors can expect a truly immersive experience across GIGABYTE and AORUS product lines such as motherboards, graphics cards, gaming monitors, and gaming laptops. As the world enters a new era of AI, GIGABYTE’s presence at COMPUTEX hints at exciting developments in the realm of AI, promising visitors a glimpse into the future of computing.

GIGABYTE will showcase cutting-edge features across its product lineup at COMPUTEX 2024. The AI Laptops including AORUS 17X and AORUS 16X steal the spotlight with the exclusive GIGABYTE AI Nexus, featuring three functions including AI Boost, enhancing performance as per specific scenarios, AI Generator for quick startups with generative AI utilities, and AI Power Gear that intelligently conserves battery life by optimizing power consumption. Additionally, the GIGABYTE GeForce RTX 40 SUPER series graphics cards are engineered to provide intense gaming and reliable AI computing power across a diverse range of applications. Complementing these advancements, the OLED Monitor series such as AORUS CO49DQ, integrates AI algorithms to introduce OLED CARE, including six key features designed to minimize burn-in risks on OLED screens and extend the screen’s lifespan.

In terms of user-friendly designs, GIGABYTE presents innovations like the EZ-Latch and Stealth Design on motherboards, streamlining PC assembly with quick and convenient installations while ensuring a clean appearance through efficient cable management. The LCD Edge View across various components like AORUS GeForce RTX 4080 SUPER MASTER enables real-time monitoring of PC performance and customizable display options. Furthermore, the GIGABYTE Arm Edition gaming monitors are equipped with ergonomic monitor mounts designed to cater to various usage environments from PC gaming, console gaming, to even streaming media, realizing the true 4K entertainment. Within the GIGABYTE OLED Gaming Monitor series, the Tactical Switch feature optimizes gaming by instant switching to a 24-inch size, 1080p resolution with a single click, specifically designed for first-person shooter games.

Additionally, GIGABYTE is proud to showcase multiple Red Dot 2024 award-winning products, including the Z790 AORUS XTREME X, Z790 AORUS MASTER X, Z790 AORUS PRO X, X670E AORUS PRO X motherboards, AORUS FO32U2P, GIGABYTE MO34WQC2 gaming monitors, and AORUS C400 GLASS gaming chassis. For more information, please visit the official GIGABYTE website at: https://bit.ly/GIGABYTE_COMPUTEX_2024

Source